Reduced Risk of Colorectal Cancer With Metformin Therapy in Patients With Type 2 Diabetes

DSpace/Manakin Repository

Reduced Risk of Colorectal Cancer With Metformin Therapy in Patients With Type 2 Diabetes

Citable link to this page

 

 
Title: Reduced Risk of Colorectal Cancer With Metformin Therapy in Patients With Type 2 Diabetes
Author: Zhang, Zhi-Jiang; Zheng, Zhi-Jie; Kan, Haidong; Song, Yiqing; Cui, Wei; Zhao, Genming; Kip, Kevin E.

Note: Order does not necessarily reflect citation order of authors.

Citation: Zhang, Zhi-Jiang, Zhi-Jie Zheng, Haidong Kan, Yiqing Song, Wei Cui, Genming Zhao, and Kevin E. Kip. 2011. Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes. Diabetes Care 34(10): 2323-2328.
Full Text & Related Files:
Abstract: Objective: Both in vitro and in vivo studies indicate that metformin inhibits cancer cell growth and reduces cancer risk. Recent epidemiological studies suggest that metformin therapy may reduce the risks of cancer and overall cancer mortality among patients with type 2 diabetes. However, data on its effect on colorectal cancer are limited and inconsistent. We therefore pooled data currently available to examine the association between metformin therapy and colorectal cancer among patients with type 2 diabetes. Research Design and Methods: The PubMed and SciVerse Scopus databases were searched to identify studies that examined the effect of metformin therapy on colorectal cancer among patients with type 2 diabetes. Summary effect estimates were derived using a random-effects meta-analysis model. Results: The analysis included five studies comprising 108,161 patients with type 2 diabetes. Metformin treatment was associated with a significantly lower risk of colorectal neoplasm (relative risk [RR] 0.63 [95% CI 0.50–0.79]; P < 0.001). After exclusion of one study that investigated colorectal adenoma, the remaining four studies comprised 107,961 diabetic patients and 589 incident colorectal cancer cases during follow-up. Metformin treatment was associated with a significantly lower risk of colorectal cancer (0.63 [0.47–0.84]; P = 0.002). There was no evidence for the presence of significant heterogeneity between the five studies (Q = 4.86, P = 0.30; I2 = 18%). Conclusions: From observational studies, metformin therapy appears to be associated with a significantly lower risk of colorectal cancer in patients with type 2 diabetes. Further investigation is warranted.
Published Version: doi:10.2337/dc11-0512
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3177711/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:10498782
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters